Serial No. 10/602.330 Docket No. 202.2D2

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

5 Claims 1-118 (Canceled)

Claim 119 (Currently amended): A method to treat or ameliorate an innate immune suppression condition by increasing the numbers of neutrophils in circulation in a human, wherein the innate immune suppression condition is associated with radiation, aging, autologous bone marrow transplantation or stem cell transplantation comprising administering to the human an effective amount about 200 mg, 250 mg or 300 mg per day of 3β,17β-dihydroxyandrost-5-ene once daily for 5 consecutive days by intramuscular, intradermal or subcutaneous administration whereby the number or activity of neutrophils in circulation in the human is increased.

Claim 120 (Canceled)

Claim 121 (Currently amended): The method of claim 120 of claim 119
wherein about 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg or 300 mg og 301 mg or 300 mg per day of 3β,17β-dihydroxyandrost-5-ene is administered.

Claim 122 (Canceled)

25 Claim 123 (Currently amended): The method ef-elaim 122 of claim 121 wherein about 200 mg per day of 3β,17β-dihydroxyandrost-5-ene is administered.

Claims 124-131 (Canceled)

30

10

15

Serial No. 10/602,330 Docket No. 202.2D2

Claim 132 (Currently amended): The method of claim 131 wherein 59-mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg or 300 mg about 300 mg per day of 3β ,17 β -dihydroxyandrost-5-ene is administered.

5 Claims 133-146 (Canceled)